NPS Pharmaceuticals Inc. (NPSP) announced Tuesday that it has re-gained the full worldwide rights to teduglutide and recombinant human parathyroid hormone 1-84 from Takeda Pharmaceutical.
NPS Pharmaceuticals gapped open higher Tuesday and is now up 1.63 at $10.67 on above average volume. The stock is now challenging the highs of the year, trading at a 5-month high.
For comments and feedback: editorial@rttnews.com